Jpmorgan Chase & CO Abb Vie Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 52,112,101 shares of ABBV stock, worth $9.3 Billion. This represents 0.84% of its overall portfolio holdings.
Number of Shares
52,112,101
Previous 53,557,915
2.7%
Holding current value
$9.3 Billion
Previous $9.19 Billion
12.03%
% of portfolio
0.84%
Previous 0.81%
Shares
14 transactions
Others Institutions Holding ABBV
# of Institutions
3,853Shares Held
1.25BCall Options Held
16.8MPut Options Held
12.2M-
Vanguard Group Inc Valley Forge, PA172MShares$30.6 Billion0.62% of portfolio
-
Black Rock Inc. New York, NY136MShares$24.3 Billion0.54% of portfolio
-
State Street Corp Boston, MA79.1MShares$14.1 Billion0.65% of portfolio
-
Morgan Stanley New York, NY38.7MShares$6.91 Billion0.56% of portfolio
-
Capital International Investors Los Angeles, CA36.8MShares$6.56 Billion1.44% of portfolio
About AbbVie Inc.
- Ticker ABBV
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,768,099,968
- Market Cap $315B
- Description
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...